Oral regimen management of acute hypertension in pregnancy

Affiliations

¹ Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Harvard Medical School, Boston, MA, USA.
² Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Harvard Medical School, Boston, MA, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: sananth.karumanchi@csmc.edu.

Free article

Comment

Elizabeth R Lemoine et al. Lancet. 2019.

Free article

. 2019 Sep 21;394(10203):981-982.

doi: 10.1016/S0140-6736(19)31717-9. Epub 2019 Aug 1.

¹ Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Harvard Medical School, Boston, MA, USA.
² Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Harvard Medical School, Boston, MA, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: sananth.karumanchi@csmc.edu.

No abstract available

Comment on

Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial.
Easterling T, Mundle S, Bracken H, Parvekar S, Mool S, Magee LA, von Dadelszen P, Shochet T, Winikoff B. Easterling T, et al. Lancet. 2019 Sep 21;394(10203):1011-1021. doi: 10.1016/S0140-6736(19)31282-6. Epub 2019 Aug 1. Lancet. 2019. PMID: 31378394 Free PMC article. Clinical Trial.